Mechanisms of Increased PE Risk in Cancer and Cancer-Type Variability
Cancer patients face substantially elevated pulmonary embolism risk through multiple prothrombotic mechanisms, and this risk varies dramatically by cancer type—with pancreatic, gastric, brain, ovarian, lung, and hematologic malignancies conferring the highest risk, while breast, prostate, and head/neck cancers carry relatively lower risk.
Why Cancer Increases PE Risk: The Mechanisms
The hypercoagulable state in cancer arises through at least four distinct pathways 1:
Direct Tumor Effects
- Endothelial damage: Both acute and chronic injury to blood vessel walls
- Procoagulant release: Tumors directly activate the coagulation cascade
- Venous compression: Particularly with peritoneal cavity tumors that impede lower extremity venous drainage 2
- Systemic inflammation: Cancer creates a pro-inflammatory milieu that activates platelets
Treatment-Related Mechanisms
Chemotherapy increases VTE risk through 1:
- Acute vascular endothelial damage
- Depletion of natural anticoagulants (protein C, protein S, antithrombin III)
- Direct platelet activation
- 7-fold increased risk when receiving active chemotherapy compared to cancer patients not on treatment 1
Antiangiogenic Agents
Drugs like bevacizumab, thalidomide, and lenalidomide cause 1:
- Endothelial cell activation and damage
- Platelet activation
- 33% relative increase in VTE with bevacizumab plus chemotherapy 1
- Up to 34% VTE rate with thalidomide-doxorubicin combinations in multiple myeloma 1
Hematologic Factors
Laboratory abnormalities that increase risk 1:
- Platelet count ≥350,000/µL
- Leukocyte count >11,000/µL
- Hemoglobin <10 g/dL or erythropoietin use
Cancer Types Do NOT Confer Equal Risk
Very High-Risk Cancers (Risk Score = 2)
- Pancreatic adenocarcinoma
- Gastric adenocarcinoma
- Brain tumors 1
High-Risk Cancers (Risk Score = 1)
- Lung cancer
- Ovarian cancer
- Kidney cancer
- Bladder cancer
- Lymphoma
- Multiple myeloma
- Gynecologic cancers
- Testicular cancer
Lower-Risk Cancers
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Head and neck cancers
Autopsy data confirms this hierarchy: ovarian cancer patients had 34.6% prevalence of PE at necropsy, extrahepatic bile duct cancer 31.7%, and gastric cancer 15.2%, while esophageal, laryngeal cancers, leukemia, and lymphoma had only 0-5.6% 2.
Quantifying the Risk: The Khorana Score
Use this validated risk assessment tool for ambulatory cancer patients starting chemotherapy 1:
| Risk Factor | Points |
|---|---|
| Very high-risk cancer site (pancreas, stomach) | 2 |
| High-risk cancer site (lung, lymphoma, GYN, bladder, testicular) | 1 |
| Platelet count ≥350,000/µL | 1 |
| Hemoglobin <10 g/dL or using ESAs | 1 |
| Leukocyte count >11,000/µL | 1 |
| BMI ≥35 kg/m² | 1 |
Risk stratification:
- Score 0: 0.3-0.5% VTE risk (low)
- Score 1-2: 2% VTE risk (intermediate)
- Score ≥3: 6.7-7% VTE risk (high) 1
Additional Risk Amplifiers
Beyond cancer type, these factors further increase PE risk 1, 3, 1:
- Metastatic/advanced stage disease (TNM III-IV): 2.38-fold increased risk
- Hospitalization: Cancer patients hospitalized have even higher baseline risk 3
- Major surgery: 3-5 fold increased risk perioperatively 4
- Central venous catheters: 1.95-fold increased risk
- Immobility and age: Standard VTE risk factors remain additive
- Obesity (BMI ≥35): Included in Khorana score
Clinical Implications
The risk is not theoretical—it's the second leading cause of death in cancer patients 5, 6. Cancer patients have:
- 4-fold higher baseline VTE risk than non-cancer patients 4
- 3-fold higher recurrence rate after initial VTE 1
- 2-fold higher bleeding risk during anticoagulation 4
- 22% probability of VTE recurrence within 6 months (vs 6.5% in non-cancer patients) 1
Common Pitfall
Do not assume all cancers carry equal thrombotic risk. A patient with localized prostate cancer on hormonal therapy has vastly different PE risk than a patient with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Risk assessment must be individualized by cancer type, stage, treatment regimen, and patient factors using tools like the Khorana score 1, 7, 8.